Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Gastroenterology

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Multilayered epithelium in a rat model and human Barrett's esophagus: Similar expression patterns of transcription factors and differentiation markers

  • Xiaoxin Chen1, 2, 3Email author,
  • Rong Qin1,
  • Ba Liu2,
  • Yan Ma1,
  • Yinghao Su4,
  • Chung S Yang2,
  • Jonathan N Glickman5,
  • Robert D Odze5 and
  • Nicholas J Shaheen3
BMC Gastroenterology20088:1

https://doi.org/10.1186/1471-230X-8-1

Received: 07 August 2007

Accepted: 11 January 2008

Published: 11 January 2008

Abstract

Background

In rats, esophagogastroduodenal anastomosis (EGDA) without concomitant chemical carcinogen treatment leads to gastroesophageal reflux disease, multilayered epithelium (MLE, a presumed precursor in intestinal metaplasia), columnar-lined esophagus, dysplasia, and esophageal adenocarcinoma. Previously we have shown that columnar-lined esophagus in EGDA rats resembled human Barrett's esophagus (BE) in its morphology, mucin features and expression of differentiation markers (Lab. Invest. 2004;84:753–765). The purpose of this study was to compare the phenotype of rat MLE with human MLE, in order to gain insight into the nature of MLE and its potential role in the development of BE.

Methods

Serial sectioning was performed on tissue samples from 32 EGDA rats and 13 patients with established BE. Tissue sections were immunohistochemically stained for a variety of transcription factors and differentiation markers of esophageal squamous epithelium and intestinal columnar epithelium.

Results

We detected MLE in 56.3% (18/32) of EGDA rats, and in all human samples. As expected, both rat and human squamous epithelium, but not intestinal metaplasia, expressed squamous transcription factors and differentiation markers (p63, Sox2, CK14 and CK4) in all cases. Both rat and human intestinal metaplasia, but not squamous epithelium, expressed intestinal transcription factors and differentiation markers (Cdx2, GATA4, HNF1α, villin and Muc2) in all cases. Rat MLE shared expression patterns of Sox2, CK4, Cdx2, GATA4, villin and Muc2 with human MLE. However, p63 and CK14 were expressed in a higher proportion of rat MLE compared to humans.

Conclusion

These data indicate that rat MLE shares similar properties to human MLE in its expression pattern of these markers, not withstanding small differences, and support the concept that MLE may be a transitional stage in the metaplastic conversion of squamous to columnar epithelium in BE.

Background

Barrett's esophagus (BE) is characterized by replacement of esophageal squamous epithelium by intestinalized columnar epithelium, most commonly due to chronic gastroesophageal reflux disease. Patients with BE are at increased risk for the development of esophageal adenocarcinoma, which is now the most rapidly increasing type of cancer in Western countries [1].

The pathogenesis of intestinal metaplasia (IM) in BE is poorly understood. For instance, theories regarding the origin of stem cells that give rise to intestinalized columnar epithelium include origin from esophageal squamous epithelium or the submucosal glands [25]. However, regardless of the site of origin, it is generally believed that pluripotent stem cells are triggered by inflammatory mediators and/or gastroesophageal refluxate to differentiate into intestinalized columnar epithelium [5, 6]. Recent studies have focused on the potential roles of acid and bile, inflammatory mediators, and intestinal transcription factors in the pathogenesis of human BE [611]. Despite these efforts, the mechanism underlying the development of IM in BE remains unclear.

Multilayered epithelium (MLE), first described in 1997, is a hybrid epithelium that expresses cytokeratins of both squamous and columnar differentiation [12]. It is composed of multiple layers of cells that appear squamous in the basal portion and columnar in the superficial aspects. Several studies have shown that MLE is predominantly located at, or near, the neo-squamocolumnar junction in patients with BE. Multilayered epithelium has also been shown to correlate with BE and reflux esophagitis. Thus, it has been postulated that MLE may represent a transitional stage in the squamous to columnar transition in BE [1316].

In our laboratory, we utilized a rat surgical model to study BE. In this model, an esophagoduodenal anastomosis was created to induce gastroesophageal reflux. Sprague-Dawley rats subjected to this procedure developed esophageal adenocarcinoma [17]. Subsequently, we modified this procedure by performing an esophagogastroduodenal anastomosis (EGDA) in order to induce reflux of gastric and duodenal contents into the esophagus. Previous studies have shown that more than 50% of rats developed columnar-lined esophagus and adenocarcinoma 40 weeks after surgery [18]. In rats, MLE frequently also occurs at the neo-squamocolumnar junction, but occasionally in the mid-esophagus as well. Rat columnar-lined esophagus resembles human BE in its morphology, mucin features and in its expression of intestinal differentiation markers, such as keratin 7, keratin 20, Das-1, villin, and trefoil factor 1 [19].

The purpose of this study was to evaluate and compare MLE in our rat model to that in humans with established BE, in order to gain further insight into the role of MLE in the development of BE. To perform this study, serial paraffin-embedded esophageal tissue sections from 32 EGDA rats were evaluated for expression patterns of transcription factors and differentiation markers of esophageal squamous epithelium and intestinal columnar epithelium not previously evaluated. Mucosal biopsy samples containing MLE from 13 human patients with established BE were also studied for comparison with the rat samples.

Methods

Tissue samples

Esophagogastroduodenal anastomosis was performed on 32 rats as described previously. [18] In brief, a surgical anastomosis was created between the gastroesophageal junction and the duodenum, on the antimesenteric border, with accurate mucosal to mucosal opposition, in 8-week-old male Sprague-Dawley rats. The animals were treated with iron dextran (4 mg Fe/kg/week, i.p.) for 40 weeks. After the animals were sacrificed by CO2 asphyxiation, the esophagus was removed, fixed in 10% buffered formalin, Swiss-rolled, processed, and embedded in paraffin. Serial sections of tissue blocks from all 32 rats (300 to 500 sections per block) were then made for this study.

For comparison, coded (with all identifiers removed) archival formalin-fixed paraffin-embedded esophageal mucosal biopsies from 13 patients with MLE in BE were obtained from the files of the Department of Pathology, Brigham and Women's Hospital, Boston, MA. The study protocol was approved by the Institutional Review Board. Ten serial sections of each case were used in this study. Tissue sections from these 13 patients were specifically selected because they all contained MLE, as described previously [16].

Pathological evaluation

In rat tissues, one out of every twenty serial tissue sections was stained with hematoxylin and eosin, and then counterstained with Alcian blue at pH2.5. Tissue sections were evaluated for the presence of BE and MLE [19]. In brief, BE was characterized by the occurrence of IM, which was defined by the presence of goblet cells in the esophagus. Multilayered epithelium consists of 4 to 8 layers of cells that show squamous differentiation in the basal portion and columnar differentiation in the superficial layers. Serial sections that contained MLE were identified and selected for immunohistochemical staining.

Tissue sections of human samples were simultaneously stained with H&E and the presence of BE and MLE was confirmed. The presence or absence of squamous epithelium was also noted.

Immunohistochemical staining

The following four groups of markers were studied (Table 1): (1) squamous transcription factors (p63, Sox2); (2) squamous differentiation markers (CK14, CK4); (3) intestinal transcription factors (Cdx2, GATA4, HNF1α); and (4) intestinal differentiation markers (villin, Muc2).
Table 1

Transcription factors and differentiation markers used in this study

Antigen

Description

Expression Pattern

Antibody Source

Catalogue No.

Conc.

p63

Transcription factor essential for squamous epithelium

Nuclei of basal and parabasal squamous cells

Santa Cruz Biotechnology (Santa Cruz, CA)

sc-8431 (mouse mAb)

0.2 μg/ml

Sox2 (SRY-related HMG box gene 2)

Transcription factor essential for upper gastrointestinal epithelium

Nuclei of epithelial cells in oral cavity, esophagus and stomach

Santa Cruz Biotechnology

sc-17320 (goat pAb)

4 μg/ml

CK14 (cytokeratin 14)

Squamous differentiation marker

Cytoplasm of basal squamous cells

Novocastra Laboratories Ltd. (Newcastle upon Tyne, UK)

NCL-LL002 (mouse mAb)

1:40

CK4 (cytokeratin 4)

Squamous differentiation marker

Cytoplasm of parabasal squamous cells

Sigma-Aldrich (St. Louis, MO)

C5176 (mouse mAb)

1:500

Cdx2 (caudal-related homeobox 2)

Intestinal transcription factor

Nuclei (and occasionally cytoplasm) of columnar and goblet cells

BioGenex (San Ramon, CA)

MU392-UC (mouse mAb)

1:50

GATA4 (GATA-binding protein 4)

Intestinal transcription factor

Nuclei of columnar and goblet cells

Santa Cruz Biotechnology

sc-1237 (goat pAb)

0.25 μg/ml

HNF1α (hepatocyte nuclear factor 1α)

Intestinal transcription factor

Nuclei of columnar and goblet cells

Santa Cruz Biotechnology

sc-6547 (goat pAb)

0.4 μg/ml

Villin

Intestinal differentiation marker

Cytoplasm of columnar and goblet cells

NeoMarkers (Fremont, CA)

MS-1499 (mouse mAb)

5 μg/ml

Muc2 (mucin 2)

Intestinal differentiation marker

Cytoplasm of goblet cells

Santa Cruz Biotechnology

sc-15334 (rabbit pAb)

1:500

Briefly, paraffin-embedded tissue sections were deparaffinized, rehydrated, and pretreated by heating the slides for 5–10 min in 10 mM citrate buffer. Immunohistochemical staining was performed with the ABC kit (Vector Labs, Capenteria, CA) according to the manufacturer's instructions. The sources of the primary antibodies, catalogue numbers, and working concentrations are listed in Table 1. Normal serum or phosphate buffered saline were used instead of the primary antibodies, as negative controls. Both positive and negative control slides were processed in parallel. Alcian blue staining (1% in 3% acetic acid, pH2.5, for 10 min) was performed after immunohistochemical staining on the same slides to visualize cells that produce acidic mucin.

Immunohistochemical staining for each marker was scored by one pathologist (R.Q.) as either positive or negative in the epithelium of interest. Areas of squamous epithelium, MLE and IM were scored separately. For analysis of p63, Sox2, Cdx2, GATA4, and HNF1α, epithelium with strong nuclear staining was counted as positive. Cytoplasmic staining of Cdx2 was also noted. Cytoplasmic staining was counted as positive for analysis of CK4, CK14, villin and Muc2. The frequency of positive staining for each marker in each epithelial type was then calculated (Table 2).
Table 2

Expression of transcription factors and differentiation markers in tissue samples from EGDA rats and humans

Antigen

EGDA Rat Samples

No. of positively stained foci/No. of total foci (%)

Human Biopsy Samples

No. of positively stained foci/No. of total foci (%)

 

Squamous epithelium

MLE

Intestinal metaplasia

Squamous epithelium

MLE

Intestinal metaplasia

p63a

128/128 (100%)

85/85 (100%)

0/142 (0%)

11/11 (100%)

5/13 (38.5%)

0/3 (0%)

Sox2

114/114 (100%)

71/71 (100%)

0/128 (0%)

11/11 (100%)

13/13 (100%)

0/3 (0%)

CK14a

113/113 (100%)

76/76 (100%)

0/139 (0%)

11/11 (100%)

0/13 (0%)

0/3 (0%)

CK4

116/116 (100%)

30/55 (54.5%)

0/129 (0%)

11/11 (100%)

4/13 (30.8%)

0/3 (0%)

Cdx2

0/114 (0%)

0/77 (0%)

127/127 (100%)

0/11 (0%)

2/13 (15.4%)

3/3 (100%)

GATA4

0/114 (0%)

0/70 (0%)

130/130 (100%)

0/11 (0%)

0/13 (0%)

2/3 (66.7%)

HNF1α

0/100 (0%)

0/54 (0%)

111/111 (100%)

N/A

N/A

N/A

Villin

0/115 (0%)

15/56 (26.8%)

133/133 (100%)

0/11 (0%)

2/13 (15.4%)

3/3 (100%)

Muc2

0/114 (0%)

0/75 (0%)

129/129 (100%)

0/11 (0%)

0/13 (0%)

3/3 (100%)

a Statistically significant difference between rat and human MLE (p < 0.0001).

Statistical analysis

Statistical analysis was conducted with Fisher exact test for frequency data. For each immunohistochemical stain, the frequency of positive staining between rat and human MLE was compared.

Results

Histopathology of rat and human samples

Twenty nine EGDA rats (29/32, 90.6%) contained BE, defined by the presence of IM in the esophagus. Multilayered epithelium was detected in 18 of 32 (56.3%) EGDA rats. The mean number of MLE foci per rat was 2.4 (range 1 to 6). Most MLE foci (91%) were located at the neo-squamocolumnar junction, whereas fewer were located distant from the junction, or in the mid-esophagus. The morphologic features of MLE in the rat model closely resembled that of human patients [14, 16, 19].

Human samples containing MLE were intentionally selected for this study. In addition, eleven samples also had squamous epithelium within their BE biopsies.

Expression of squamous transcription factors and differentiation markers in rat and human samples (Figure 1; Table 2)

Figure 1

Expression of squamous transcription factors (p63, Sox2) and differentiation markers (CK4, Ck14) in squamous epithelium, MLE and IM of EGDA rats and humans. All the tissue sections were stained immunohistochemically with a specific antibody, and then histochemically with Alcian blue. Light blue: Alcian blue staining of acidic mucin; dark blue: hematoxylin staining for nuclei; dark brown: immunohistochemical staining. Size bar equals 20 μm in rat samples, or 40 μm in human samples.

Both rat and human squamous epithelium uniformly expressed squamous transcription factors (p63 and Sox2) and differentiation markers (CK14 and CK4) in all cases (Figure 1A, D, G, J, M, P, S, V). P63 and Sox2 were both expressed in the nuclei of squamous epithelial cells in the basal cell layer. CK14 was expressed in the cytoplasm of basal cells, and CK4 in suprabasal cells.

Neither rat nor human IM expressed any of these transcription factors or differentiation markers (Figure 1C, F, I, L, O, R, U, X).

Both rat and human MLE expressed squamous transcription factor, Sox2, in the nuclei of basal cell layer of all cases (Figure 1E, Q), similar to squamous epithelium. p63 was expressed in 100% (85/85) of rat MLE (Figure 1B). However, only 38.5% (5/13) of human MLE (Figure 1N) expressed p63 (p < 0.0001 vs. rat MLE).

Of the two squamous differentiation markers (CK14 and CK4), CK14 was expressed in basal cells of rat MLE in all cases, similar to squamous epithelium (Figure 1H). However, in human MLE, CK14 was negative in all 13 cases (p < 0.0001, vs. rat MLE; Figure 1T). CK4 was expressed in 54.5% (30/55) of rat MLE (Figure 1K), and in 30.8% (4/13) of human MLE (Figure 1W). Such a difference was not statistically significant (p > 0.05).

Expression of intestinal transcription factors and differentiation markers in rat and human samples (Figure 2; Table 2)

Figure 2

Expression of intestinal transcription factors (Cdx2, GATA4, HNF1α) and differentiation markers (villin, Muc2) in MLE and IM of EGDA rats and humans. All the tissue sections were stained immunohistochemically with a specific antibody, and then histochemically with Alcian blue. Light blue: Alcian blue staining of acidic mucin; dark blue: hematoxylin staining for nuclei; dark brown: immunohistochemical staining. Size bar equals 20 μm in rat samples, or 40 μm in human samples.

Neither rat nor human squamous epithelium expressed any of the intestinal transcription factors (Cdx2, GATA4 and HNF1α) and differentiation markers (villin and Muc2) (figures not shown). However, both rat IM (Figure 2B, D, F, H) and human IM (Figure 2J, L, N, P) expressed all intestinal markers studied, except for one case of human IM in which GATA4 was not expressed.

Rat MLE did not express Cdx2, GATA4, and HNF1α (Figure 2A, C, E) in any of the cases. Similar to rat MLE, human MLE did not express GATA4 and Muc2 (Figure 2K, M). Interestingly although Cdx2 was not expressed in the nuclei in any cases, it was detected in the cytoplasm of two cases (Figure 2I).

Villin, an intestinal differentiation marker, was expressed in 26.8% (15/56) of rat MLE (Figure 2G), and in 15.4% (2/13) of human MLE (Figure 2O). Such a difference was not statistically significant (p > 0.05).

Discussion

Multilayered epithelium, a hybrid epithelium consisting of squamous cells in the basal portion and columnar cells in the superficial layers, was first described in esophageal biopsies in patients with BE [16]. Human MLE expressed differentiation markers of both squamous and intestinal columnar epithelium, suggesting that it might represent a transitional stage in the metaplastic conversion of squamous to columnar epithelium in BE [12, 14]. In this study, we compared the phenotype of rat MLE versus human MLE in order to gain further insight into the nature of MLE, and its potential role in the development of BE.

We focused on squamous transcription factors (p63, Sox2) and differentiation markers (CK4, CK14), and intestinal transcription factors (Cdx2, GTAT4, HNF1α) and differentiation markers (villin, Muc2). Transcription factors represent "master switch" genes, which regulate expression of differentiation-related molecules with both structural and functional specificity, and, thus, mediate metaplasia. Using immunohistochemical staining we found that both rat and human MLE simultaneously expressed markers of both squamous and intestinal differentiation, and that with minor exceptions, rat and human MLE shared similar expression patterns of these markers. For instance, we found that rat MLE is more likely to express p63 and CK14 compared to human MLE.

The squamous transcription factors and differentiation markers evaluated in this study include p63, Sox2, CK4 and CK14. P63 is a critical initiator of epithelial stratification and a key regulator of cell adhesion and survival in progenitor cells in squamous epithelium [2022]. In mouse esophagus, when basal cells become differentiated, p63 is down-regulated and eventually turned off in terminally differentiated superficial cells [15, 23]. In p63-deficient mice, embryonic esophageal epithelium appears columnar containing both ciliated and goblet-like cells [24]. Previous studies have shown that p63 is expressed in the basal and suprabasal cell layers, and in submucosal glands, of human esophageal squamous epithelium [15, 25]. p63 in esophageal epithelial cells was downregulated when they were exposed to bile and acid [26]. In this study, p63 was detected in all cases of rat MLE, but in only 38.5% (5/13) of human MLE (p < 0.0001). This result suggests that rat and human MLE show differences in their native esophageal epithelium, and that basal cells of rat MLE maintain a higher degree of "squamous" differentiation compared to rat MLE. It is known that rat esophagus is covered by keratinized squamous epithelium and human esophagus by non-keratinized squamous epithelium.

As a member of the Sry-like high mobility group domain protein family, Sox2 may play an important role in the development of the upper gastrointestinal tract. It is expressed in the pharynx, esophagus, and stomach of chicken gut, but not in the lower gastrointestinal tract, where Cdx1 and Cdx2 are present and play an important role in cell differentiation [27, 28]. Sox2 mutations are associated with esophageal atresia in anophthalmia-esophageal-genital syndrome [29], and its down-regulation is associated with intestinal metaplasia in the stomach [30, 31]. Hypomorphic Sox2 mice developed metaplastic changes of morphology and gene expression in the esophagus [32]. Our data showed that Sox2 was expressed in both rat and human MLE in all cases. In intestinal metaplasia, Sox2 was negative in both rat and human samples. Recently, Sox2 was reported to be silenced by promoter methylation in intestinal-type gastric cancer [33]. Further studies are needed to understand the mechanisms by which Sox2 is turned off in metaplastic columnar epithelium.

CK4 and CK14 are differentiation markers of esophageal squamous epithelium. CK14 is typically expressed in basal cells and CK4 in parabasal cells [34]. Interestingly, in our study, CK14 was not expressed in human MLE, but it was expressed in all cases of rat MLE. This expression pattern was similar to that of p63 in rat and human MLE, likely due to the fact that CK14 is a transcriptional target of p63 [35]. Nevertheless, these data support the theory that rat MLE maintains a higher level of "squamous" differentiation compared to human MLE. In the presence of gastroesophageal reflux, human esophagus was more likely to lose squamous differentiation features.

We also evaluated intestinal transcription factors (Cdx2, GATA4 and HNF1α) and differentiation markers (villin and Muc2). As a member of the Caudal-related homeobox gene family, Cdx2 is important for skeletal and intestinal development. Cdx2 plays an important regulatory role in the development of intestinal metaplasia in the foregut, and in cancer development in the colon [36, 37]. Cdx2 is normally not expressed in squamous cells of the normal human esophagus. However, one previous study showed that a low level of Cdx2 mRNA was detected in biopsy samples of esophageal squamous epithelium in patients with esophagitis [11, 38]. In BE, Cdx2 is expressed in goblet and non-goblet cells [39]. In fact, several Cdx2-regulated genes are known "markers" of BE, such as villin, guanylate cyclase C, and sucrase isomaltase [4042]. We recently demonstrated that treatment of esophageal epithelial cells with acid, bile acids or both resulted in promoter demethylation and activation of Cdx2 [43]. In this study, Cdx2 was negative in all rat MLE samples, which suggests that Cdx2 is not expressed at an early stage of columnar metaplasia. However, in human MLE, two cases expressed Cdx2 in the cytoplasm, although none of them showed nuclear expression. Similarly, cytoplasmic expression of Cdx2 has been reported in the columnar epithelium of colon, bile duct and stomach [4446]. The significance of cytoplasmic accumulation of Cdx2 is still unclear.

GATA4 belongs to a subfamily of the GATA transcription factor family involved in differentiation of mesoderm and endoderm-derived tissues. GATA4, 5 and 6 are expressed in the stomach and small intestine, but not in the esophagus [4749]. HNF1α is a liver-enriched homeodomain-containing transcription factor, which regulates many genes in liver and pancreas [50, 51]. Intestinal transcriptional factors (GATA4, HNF1α, and Cdx2) have been shown to play cooperative roles in regulating the expression of several marker genes in intestinal epithelium and human BE [40, 50, 51]. In this study, neither rat nor human MLE expressed GATA4 or HNF1α, suggesting that GATA4 and HNF1α are probably not involved at an early stage of conversion from squamous to columnar epithelium in the esophagus.

Villin is an actin-bundling protein and a marker of human BE [19, 5254]. Muc2 is a differentiation marker of intestinal and tracheobronchial goblet cells [55], and is known to be regulated by Cdx2 in esophageal epithelial cells [9, 43]. In this study, villin was expressed in a small percentage of rat and human MLE, whereas Muc2 was not expressed in either type of tissues. These data suggest that the mucinous cells in MLE do not possess some biological properties of fully developed goblet cells. It is possible that, during the metaplastic conversion of squamous to columnar epithelium, villin is expressed at an early phase, whereas Muc2 is expressed only when phenotypically mature goblet cells develop. Although villin is a possible transcriptional target of Cdx2 [41], our data suggest that other factors may regulate its expression in MLE.

The mechanism of intestinal metaplasia is still unclear. Our data in rat model strongly support the theory that stem cells reside in the esophagus. Three theories have been proposed for the development of intestinal metaplasia in human BE. The de novo metaplasia theory proposes that the stem cells of inflamed squamous epithelium are stimulated by reflux to undergo columnar metaplasia. The transitional zone metaplasia theory suggests that epithelial cells at the squamocolumnar junction colonize the gastric cardia or distal esophagus in response to reflux. The esophageal gland duct cell metaplasia theory proposes that stem cells are located in the neck of submucosal gland ducts, and they are stimulated to expand upon deep ulceration of the mucosa and submucosa [5]. However, rats do not have submucosal glands or ducts in their esophagus, and rat MLE is commonly found in the mid-esophagus unrelated to the neo-squamocolumnar junction after EGDA surgery. Thus, development of MLE in EGDA rats supports pluripotent stem cells in the esophagus as the cellular origin of intestinal metaplasia. This hypothesis is consistent with previous studies suggesting gut regenerative cell lineage as the likely cellular origin of BE [56]. Although MLE is likely a precursor lesion of BE, it can not be excluded that MLE may be a distinct multi-directional differentiation type of epithelium, which may not develop into BE.

Conclusion

In summary, this study shows that rat MLE is similar to human MLE in the expression pattern of markers of squamous and intestinal differentiation. Further studies are warranted to determine how these markers are modulated by gastroesophageal reflux, and how they cooperate with each other to facilitate columnar metaplasia.

Abbreviations

BE: 

Barrett's esophagus

Cdx: 

caudal-related homeobox

CK: 

Cytokeratin

EGDA: 

Esophagogastroduodenal anastomosis

GATA4: 

GATA-binding protein 4

HNF1: 

Hepatocyte nuclear factor 1α

IM: 

Intestinal metaplasia

MLE: 

Multilayered epithelium

Muc2: 

Mucin 2

Sox2: 

SRY-related HMG box gene 2.

Declarations

Acknowledgements

This project is supported by NIH grants CA75683, DK63650 and CA092077, and the Dave Brumitt Foundation.

Authors’ Affiliations

(1)
Cancer Research Program, Julius L. Chambers Biomedical/Biotechnology Research Institute, North Carolina Central University
(2)
Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey
(3)
Center of Esophageal Diseases and Swallowing, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill
(4)
Department of Medicine and Center for Health Services Research, Vanderbilt University Medical Center
(5)
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School

References

  1. Chen X, Yang CS: Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention. Carcinogenesis. 2001, 22 (8): 1119-1129. 10.1093/carcin/22.8.1119.View ArticlePubMedGoogle Scholar
  2. Guillem PG: How to make a Barrett esophagus: pathophysiology of columnar metaplasia of the esophagus. Dig Dis Sci. 2005, 50 (3): 415-424. 10.1007/s10620-005-2451-x.View ArticlePubMedGoogle Scholar
  3. Orlando RC: Pathogenesis of reflux esophagitis and Barrett's esophagus. Med Clin North Am. 2005, 89 (2): 219-41, vii. 10.1016/j.mcna.2004.08.006.View ArticlePubMedGoogle Scholar
  4. Shaheen NJ: Advances in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology. 2005, 128 (6): 1554-1566. 10.1053/j.gastro.2005.03.032.View ArticlePubMedGoogle Scholar
  5. Jankowski JA, Harrison RF, Perry I, Balkwill F, Tselepis C: Barrett's metaplasia. Lancet. 2000, 356 (9247): 2079-2085. 10.1016/S0140-6736(00)03411-5.View ArticlePubMedGoogle Scholar
  6. Fitzgerald RC: Barrett's oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation?. Gut. 2005, 54 Suppl 1: i21-6. 10.1136/gut.2004.041558.View ArticlePubMedGoogle Scholar
  7. Wong NA, Wilding J, Bartlett S, Liu Y, Warren BF, Piris J, Maynard N, Marshall R, Bodmer WF: CDX1 is an important molecular mediator of Barrett's metaplasia. Proc Natl Acad Sci U S A. 2005, 102 (21): 7565-7570. 10.1073/pnas.0502031102.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Tselepis C, Perry I, Dawson C, Hardy R, Darnton SJ, McConkey C, Stuart RC, Wright N, Harrison R, Jankowski JA: Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action. Oncogene. 2002, 21 (39): 6071-6081. 10.1038/sj.onc.1205731.View ArticlePubMedGoogle Scholar
  9. Kazumori H, Ishihara S, Rumi MA, Kadowaki Y, Kinoshita Y: Bile acids directly augment caudal related homeobox gene Cdx2 expression in oesophageal keratinocytes in Barrett's epithelium. Gut. 2006, 55 (1): 16-25. 10.1136/gut.2005.066209.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Marchetti M, Caliot E, Pringault E: Chronic acid exposure leads to activation of the cdx2 intestinal homeobox gene in a long-term culture of mouse esophageal keratinocytes. J Cell Sci. 2003, 116 (Pt 8): 1429-1436. 10.1242/jcs.00338.View ArticlePubMedGoogle Scholar
  11. Eda A, Osawa H, Satoh K, Yanaka I, Kihira K, Ishino Y, Mutoh H, Sugano K: Aberrant expression of CDX2 in Barrett's epithelium and inflammatory esophageal mucosa. J Gastroenterol. 2003, 38 (1): 14-22. 10.1007/s005350300001.View ArticlePubMedGoogle Scholar
  12. Boch JA, Shields HM, Antonioli DA, Zwas F, Sawhney RA, Trier JS: Distribution of cytokeratin markers in Barrett's specialized columnar epithelium. Gastroenterology. 1997, 112 (3): 760-765. 10.1053/gast.1997.v112.pm9041237.View ArticlePubMedGoogle Scholar
  13. Upton MP, Nishioka NS, Ransil BJ, Rosenberg SJ, Puricelli WP, Zwas FR, Shields HM: Multilayered epithelium may be found in patients with Barrett's epithelium and dysplasia or adenocarcinoma. Dig Dis Sci. 2006, 51 (10): 1783-1790. 10.1007/s10620-006-9243-9.View ArticlePubMedGoogle Scholar
  14. Glickman JN, Chen YY, Wang HH, Antonioli DA, Odze RD: Phenotypic characteristics of a distinctive multilayered epithelium suggests that it is a precursor in the development of Barrett's esophagus. Am J Surg Pathol. 2001, 25 (5): 569-578. 10.1097/00000478-200105000-00002.View ArticlePubMedGoogle Scholar
  15. Glickman JN, Yang A, Shahsafaei A, McKeon F, Odze RD: Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. Hum Pathol. 2001, 32 (11): 1157-1165. 10.1053/hupa.2001.28951.View ArticlePubMedGoogle Scholar
  16. Shields HM, Rosenberg SJ, Zwas FR, Ransil BJ, Lembo AJ, Odze R: Prospective evaluation of multilayered epithelium in Barrett's esophagus. Am J Gastroenterol. 2001, 96 (12): 3268-3273. 10.1111/j.1572-0241.2001.05324.x.View ArticlePubMedGoogle Scholar
  17. Goldstein SR, Yang GY, Curtis SK, Reuhl KR, Liu BC, Mirvish SS, Newmark HL, Yang CS: Development of esophageal metaplasia and adenocarcinoma in a rat surgical model without the use of a carcinogen. Carcinogenesis. 1997, 18 (11): 2265-2270. 10.1093/carcin/18.11.2265.View ArticlePubMedGoogle Scholar
  18. Chen X, Yang G, Ding WY, Bondoc F, Curtis SK, Yang CS: An esophagogastroduodenal anastomosis model for esophageal adenocarcinogenesis in rats and enhancement by iron overload. Carcinogenesis. 1999, 20 (9): 1801-1808. 10.1093/carcin/20.9.1801.View ArticlePubMedGoogle Scholar
  19. Su Y, Chen X, Klein M, Fang M, Wang S, Yang CS, Goyal RK: Phenotype of columnar-lined esophagus in rats with esophagogastroduodenal anastomosis: similarity to human Barrett's esophagus. Lab Invest. 2004, 84 (6): 753-765. 10.1038/labinvest.3700079.View ArticlePubMedGoogle Scholar
  20. Koster MI, Kim S, Mills AA, DeMayo FJ, Roop DR: p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev. 2004, 18 (2): 126-131. 10.1101/gad.1165104.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Koster MI, Kim S, Roop DR: P63 deficiency: a failure of lineage commitment or stem cell maintenance?. J Investig Dermatol Symp Proc. 2005, 10 (2): 118-123. 10.1111/j.1087-0024.2005.200416.x.View ArticlePubMedGoogle Scholar
  22. Carroll DK, Carroll JS, Leong CO, Cheng F, Brown M, Mills AA, Brugge JS, Ellisen LW: p63 regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol. 2006, 8 (6): 551-561. 10.1038/ncb1420.View ArticlePubMedGoogle Scholar
  23. Daniely Y, Liao G, Dixon D, Linnoila RI, Lori A, Randell SH, Oren M, Jetten AM: Critical role of p63 in the development of a normal esophageal and tracheobronchial epithelium. Am J Physiol Cell Physiol. 2004, 287 (1): C171-81. 10.1152/ajpcell.00226.2003.View ArticlePubMedGoogle Scholar
  24. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, Tabin C, Sharpe A, Caput D, Crum C, McKeon F: p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature. 1999, 398 (6729): 714-718. 10.1038/19539.View ArticlePubMedGoogle Scholar
  25. Geddert H, Kiel S, Heep HJ, Gabbert HE, Sarbia M: The role of p63 and deltaNp63 (p40) protein expression and gene amplification in esophageal carcinogenesis. Hum Pathol. 2003, 34 (9): 850-856. 10.1016/S0046-8177(03)00342-3.View ArticlePubMedGoogle Scholar
  26. Roman S, Petre A, Thepot A, Hautefeuille A, Scoazec JY, Mion F, Hainaut P: Downregulation of p63 upon exposure to bile salts and acid in normal and cancer esophageal cells in culture. Am J Physiol Gastrointest Liver Physiol. 2007, 293 (1): G45-53. 10.1152/ajpgi.00583.2006.View ArticlePubMedGoogle Scholar
  27. Ishii Y, Rex M, Scotting PJ, Yasugi S: Region-specific expression of chicken Sox2 in the developing gut and lung epithelium: regulation by epithelial-mesenchymal interactions. Dev Dyn. 1998, 213 (4): 464-475. 10.1002/(SICI)1097-0177(199812)213:4<464::AID-AJA11>3.0.CO;2-Z.View ArticlePubMedGoogle Scholar
  28. Kamachi Y, Uchikawa M, Kondoh H: Pairing SOX off: with partners in the regulation of embryonic development. Trends Genet. 2000, 16 (4): 182-187. 10.1016/S0168-9525(99)01955-1.View ArticlePubMedGoogle Scholar
  29. Williamson KA, Hever AM, Rainger J, Rogers RC, Magee A, Fiedler Z, Keng WT, Sharkey FH, McGill N, Hill CJ, Schneider A, Messina M, Turnpenny PD, Fantes JA, van Heyningen V, FitzPatrick DR: Mutations in SOX2 cause anophthalmia-esophageal-genital (AEG) syndrome. Hum Mol Genet. 2006, 15 (9): 1413-1422. 10.1093/hmg/ddl064.View ArticlePubMedGoogle Scholar
  30. Tsukamoto T, Inada K, Tanaka H, Mizoshita T, Mihara M, Ushijima T, Yamamura Y, Nakamura S, Tatematsu M: Down-regulation of a gastric transcription factor, Sox2, and ectopic expression of intestinal homeobox genes, Cdx1 and Cdx2: inverse correlation during progression from gastric/intestinal-mixed to complete intestinal metaplasia. J Cancer Res Clin Oncol. 2004, 130 (3): 135-145. 10.1007/s00432-003-0519-6.View ArticlePubMedGoogle Scholar
  31. Tsukamoto T, Mizoshita T, Mihara M, Tanaka H, Takenaka Y, Yamamura Y, Nakamura S, Ushijima T, Tatematsu M: Sox2 expression in human stomach adenocarcinomas with gastric and gastric-and-intestinal-mixed phenotypes. Histopathology. 2005, 46 (6): 649-658. 10.1111/j.1365-2559.2005.02170.x.View ArticlePubMedGoogle Scholar
  32. Que J, Okubo T, Goldenring JR, Nam KT, Kurotani R, Morrisey EE, Taranova O, Pevny LH, Hogan BL: Multiple dose-dependent roles for Sox2 in the patterning and differentiation of anterior foregut endoderm. Development. 2007, 134 (13): 2521-2531. 10.1242/dev.003855.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Otsubo T, Akiyama Y, Yuasa Y: Sox2 inhibits growth of gastric epithelial cell lines through cell cycle arrest and apoptosis. Proc AACR. 2007, 48: A1239-Google Scholar
  34. Viaene AI, Baert JH: Expression of cytokeratin mRNAs in normal human esophageal epithelium. Anat Rec. 1995, 241 (1): 88-98. 10.1002/ar.1092410112.View ArticlePubMedGoogle Scholar
  35. Romano RA, Birkaya B, Sinha S: A functional enhancer of keratin14 is a direct transcriptional target of deltaNp63. J Invest Dermatol. 2007, 127 (5): 1175-1186. 10.1038/sj.jid.5700652.View ArticlePubMedGoogle Scholar
  36. Guo RJ, Suh ER, Lynch JP: The role of cdx proteins in intestinal development and cancer. Cancer Biol Ther. 2004, 3 (7): 593-601.View ArticlePubMedGoogle Scholar
  37. Silberg DG, Swain GP, Suh ER, Traber PG: Cdx1 and cdx2 expression during intestinal development. Gastroenterology. 2000, 119 (4): 961-971. 10.1053/gast.2000.18142.View ArticlePubMedGoogle Scholar
  38. Silberg DG, Furth EE, Taylor JK, Schuck T, Chiou T, Traber PG: CDX1 protein expression in normal, metaplastic, and neoplastic human alimentary tract epithelium. Gastroenterology. 1997, 113 (2): 478-486. 10.1053/gast.1997.v113.pm9247467.View ArticlePubMedGoogle Scholar
  39. Groisman GM, Amar M, Meir A: Expression of the intestinal marker Cdx2 in the columnar-lined esophagus with and without intestinal (Barrett's) metaplasia. Mod Pathol. 2004, 17 (10): 1282-1288. 10.1038/modpathol.3800182.View ArticlePubMedGoogle Scholar
  40. Boudreau F, Rings EH, van Wering HM, Kim RK, Swain GP, Krasinski SD, Moffett J, Grand RJ, Suh ER, Traber PG: Hepatocyte nuclear factor-1 alpha, GATA-4, and caudal related homeodomain protein Cdx2 interact functionally to modulate intestinal gene transcription. Implication for the developmental regulation of the sucrase-isomaltase gene. J Biol Chem. 2002, 277 (35): 31909-31917. 10.1074/jbc.M204622200.View ArticlePubMedGoogle Scholar
  41. Braunstein EM, Qiao XT, Madison B, Pinson K, Dunbar L, Gumucio DL: Villin: A marker for development of the epithelial pyloric border. Dev Dyn. 2002, 224 (1): 90-102. 10.1002/dvdy.10091.View ArticlePubMedGoogle Scholar
  42. Park J, Schulz S, Waldman SA: Intestine-specific activity of the human guanylyl cyclase C promoter is regulated by Cdx2. Gastroenterology. 2000, 119 (1): 89-96. 10.1053/gast.2000.8520.View ArticlePubMedGoogle Scholar
  43. Liu T, Zhang X, So CK, Wang S, Wang P, Yan L, Myers R, Chen Z, Patterson AP, Yang CS, Chen X: Regulation of Cdx2 expression by promoter methylation, and effects of Cdx2 transfection on morphology and gene expression of human esophageal epithelial cells. Carcinogenesis. 2007, 28 (2): 488-496. 10.1093/carcin/bgl176.View ArticlePubMedGoogle Scholar
  44. Hinoi T, Loda M, Fearon ER: Silencing of CDX2 expression in colon cancer via a dominant repression pathway. J Biol Chem. 2003, 278 (45): 44608-44616. 10.1074/jbc.M307435200.View ArticlePubMedGoogle Scholar
  45. Ishikawa A, Sasaki M, Ohira S, Ohta T, Oda K, Nimura Y, Chen MF, Jan YY, Yeh TS, Nakanuma Y: Aberrant expression of CDX2 is closely related to the intestinal metaplasia and MUC2 expression in intraductal papillary neoplasm of the liver in hepatolithiasis. Lab Invest. 2004, 84 (5): 629-638. 10.1038/labinvest.3700087.View ArticlePubMedGoogle Scholar
  46. Satoh K, Mutoh H, Eda A, Yanaka I, Osawa H, Honda S, Kawata H, Kihira K, Sugano K: Aberrant expression of CDX2 in the gastric mucosa with and without intestinal metaplasia: effect of eradication of Helicobacter pylori. Helicobacter. 2002, 7 (3): 192-198. 10.1046/j.1523-5378.2002.00080.x.View ArticlePubMedGoogle Scholar
  47. Molkentin JD: The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed regulators of tissue-specific gene expression. J Biol Chem. 2000, 275 (50): 38949-38952. 10.1074/jbc.R000029200.View ArticlePubMedGoogle Scholar
  48. Jacobsen CM, Narita N, Bielinska M, Syder AJ, Gordon JI, Wilson DB: Genetic mosaic analysis reveals that GATA-4 is required for proper differentiation of mouse gastric epithelium. Dev Biol. 2002, 241 (1): 34-46. 10.1006/dbio.2001.0424.View ArticlePubMedGoogle Scholar
  49. Sakamoto N, Fukuda K, Watanuki K, Sakai D, Komano T, Scotting PJ, Yasugi S: Role for cGATA-5 in transcriptional regulation of the embryonic chicken pepsinogen gene by epithelial-mesenchymal interactions in the developing chicken stomach. Dev Biol. 2000, 223 (1): 103-113. 10.1006/dbio.2000.9731.View ArticlePubMedGoogle Scholar
  50. Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, Murray HL, Volkert TL, Schreiber J, Rolfe PA, Gifford DK, Fraenkel E, Bell GI, Young RA: Control of pancreas and liver gene expression by HNF transcription factors. Science. 2004, 303 (5662): 1378-1381. 10.1126/science.1089769.View ArticlePubMedPubMed CentralGoogle Scholar
  51. Gregory PA, Lewinsky RH, Gardner-Stephen DA, Mackenzie PI: Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. Toxicol Appl Pharmacol. 2004, 199 (3): 354-363. 10.1016/j.taap.2004.01.008.View ArticlePubMedGoogle Scholar
  52. Kumble S, Omary MB, Fajardo LF, Triadafilopoulos G: Multifocal heterogeneity in villin and Ep-CAM expression in Barrett's esophagus. Int J Cancer. 1996, 66 (1): 48-54. 10.1002/(SICI)1097-0215(19960328)66:1<48::AID-IJC9>3.0.CO;2-Z.View ArticlePubMedGoogle Scholar
  53. MacLennan AJ, Orringer MB, Beer DG: Identification of intestinal-type Barrett's metaplasia by using the intestine-specific protein villin and esophageal brush cytology. Mol Carcinog. 1999, 24 (2): 137-143. 10.1002/(SICI)1098-2744(199902)24:2<137::AID-MC8>3.0.CO;2-A.View ArticlePubMedGoogle Scholar
  54. Regalado SP, Nambu Y, Iannettoni MD, Orringer MB, Beer DG: Abundant expression of the intestinal protein villin in Barrett's metaplasia and esophageal adenocarcinomas. Mol Carcinog. 1998, 22 (3): 182-189. 10.1002/(SICI)1098-2744(199807)22:3<182::AID-MC6>3.0.CO;2-N.View ArticlePubMedGoogle Scholar
  55. Gendler SJ, Spicer AP: Epithelial mucin genes. Annu Rev Physiol. 1995, 57: 607-634. 10.1146/annurev.ph.57.030195.003135.View ArticlePubMedGoogle Scholar
  56. Kumagai H, Mukaisho K, Sugihara H, Bamba M, Miyashita T, Miwa K, Hattori T: Cell kinetic study on histogenesis of Barrett's esophagus using rat reflux model. Scand J Gastroenterol. 2003, 38 (7): 687-692. 10.1080/00365520310003435.View ArticlePubMedGoogle Scholar
  57. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-230X/8/1/prepub

Copyright

© Chen et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement